🇺🇸 FDA

Intelligence Platform

Patents

Browse 454 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9617596

Biomarkers predictive for clinical response for glatiramer acetate

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9611322

Fusions of antibodies to CD38 and attenuated interferon alpha

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Apr 04 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9592291

Methods for iontophoretically treating nausea and migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Mar 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9585878

Treatment of BDNF-related disorders using laquinimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9505826

Modified antibody with improved half-life

TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Granted Tue Nov 29 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9499868

Determination of single nucleotide polymorphisms useful to predict response for glatiramer

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9427578

Pharmacokinetics of iontophoretic sumatriptan administration

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Aug 30 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9415008

Dry powder inhaler

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue Aug 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9409662

Formulations of albu-BChE, preparation and uses thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Aug 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9382200

Process for the preparation of and crystalline forms of optical enantiomers of modafinil

Teva Sante · Granted Tue Jul 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 30 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9375403

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jun 28 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9364540

Inhalable medicament

Teva Branded Pharmaceutical Products R&D, Inc. · Granted Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9346746

R(+)-N-formyl-propargyl-aminoindan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 24 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9339469

R(+)-N-methyl-propargyl-aminoindan

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340307

Stable laquinimod preparations

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9308182

Parenteral formulations of rasagiline

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9284276

N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, prepara

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9272137

Transdermal methods and systems for the delivery of anti-migraine compounds

TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9233927

Crystals of laquinimod sodium and improved process for the manufacture thereof

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Jan 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9220692

Methods of reducing symptoms in subjects using single dosage forms with tapering release r

TEVA WOMEN'S HEALTH, INC. · Granted Tue Dec 29 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9186333

Process for preparing pharmaceutical compositions of fingolimod

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9180097

Formulations of 6-mercaptopurine

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Nov 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161935

Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF the

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9161936

Laquinimod for treatment of GABA mediated disorders

TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Tue Oct 20 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted